Assenagon Asset Management S.A. Makes New Investment in uniQure N.V. $QURE

Assenagon Asset Management S.A. bought a new stake in uniQure N.V. (NASDAQ:QURE) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 606,923 shares of the biotechnology company’s stock, valued at approximately $14,524,000. Assenagon Asset Management S.A. owned about 0.97% of uniQure as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. Private Trust Co. NA bought a new position in uniQure during the third quarter valued at $28,000. Jones Financial Companies Lllp raised its stake in shares of uniQure by 509.0% in the third quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company’s stock valued at $33,000 after buying an additional 509 shares during the period. CIBC Private Wealth Group LLC purchased a new position in shares of uniQure during the 3rd quarter valued at $50,000. FNY Investment Advisers LLC lifted its position in shares of uniQure by 76.7% during the 3rd quarter. FNY Investment Advisers LLC now owns 1,654 shares of the biotechnology company’s stock valued at $96,000 after buying an additional 718 shares during the last quarter. Finally, Tower Research Capital LLC TRC grew its stake in shares of uniQure by 358.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 7,085 shares of the biotechnology company’s stock worth $99,000 after acquiring an additional 5,538 shares during the period. 78.83% of the stock is owned by institutional investors.

Insider Activity

In other uniQure news, insider Jeannette Potts sold 3,412 shares of the company’s stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $9.06, for a total value of $30,912.72. Following the completion of the sale, the insider owned 138,483 shares of the company’s stock, valued at $1,254,655.98. This represents a 2.40% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Matthew C. Kapusta sold 14,581 shares of the stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $9.06, for a total transaction of $132,103.86. Following the transaction, the chief executive officer owned 660,658 shares in the company, valued at $5,985,561.48. The trade was a 2.16% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 81,399 shares of company stock worth $1,527,645. 4.79% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on QURE. TD Cowen restated a “buy” rating on shares of uniQure in a research note on Tuesday, March 3rd. Mizuho upgraded shares of uniQure from a “neutral” rating to an “outperform” rating and increased their target price for the stock from $12.00 to $35.00 in a research report on Wednesday, March 11th. Chardan Capital lifted their target price on shares of uniQure from $16.00 to $31.00 and gave the stock a “buy” rating in a research note on Monday, March 9th. Leerink Partners reissued an “outperform” rating and issued a $35.00 price target on shares of uniQure in a research report on Monday, March 2nd. Finally, Sanford C. Bernstein cut shares of uniQure to a “market perform” rating in a research note on Tuesday, March 3rd. Ten equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, uniQure presently has a consensus rating of “Moderate Buy” and a consensus target price of $42.75.

Key Stories Impacting uniQure

Here are the key news stories impacting uniQure this week:

• Negative Sentiment: Multiple law firms have launched or publicized securities‑fraud investigations and class actions against uniQure, citing events around late‑Sept to Oct 2025 and urging investors to seek lead‑plaintiff status by April 13, 2026 — increasing potential litigation exposure and near‑term headline risk. QURE SHAREHOLDER ALERT: Hagens Berman Updates uniQure (QURE) Investigation
• Negative Sentiment: A securities class action has been filed and multiple firms (Bernstein Liebhard, Pomerantz, Rosen, Levi & Korsinsky, Faruqi & Faruqi, Kessler Topaz, KSF, ClaimsFiler) are soliciting plaintiffs — consolidation of suits or a lead plaintiff could accelerate discovery and settlement risk. SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against uniQure N.V
• Negative Sentiment: FDA publicly rebuked uniQure and there are allegations of “distorted” data and an FDA approval delay referenced by plaintiffs — regulatory criticism raises the chance of additional review, label or approval setbacks that would materially affect future revenue expectations. QURE ALERT: Hagens Berman Updates uniQure Investigation Following Public FDA Rebukes
• Negative Sentiment: Analyst action: Barclays lowered its price target to $25 and the shares were downgraded by at least one analyst, increasing selling pressure as forecasts and investor expectations are trimmed. Barclays Lowers uniQure (NASDAQ:QURE) Price Target to $25.00
• Negative Sentiment: Background gravity: some notices cite a prior ~49% share decline tied to the FDA delay, underscoring that litigation and regulatory developments have already driven significant investor losses and could prolong volatility. uniQure N.V. Securities Fraud Class Action Result of FDA Approval Delay and 49% Stock Decline

uniQure Trading Down 4.6%

Shares of uniQure stock opened at $15.60 on Friday. uniQure N.V. has a 1 year low of $7.76 and a 1 year high of $71.50. The firm has a market cap of $975.47 million, a PE ratio of -4.52 and a beta of 0.73. The company has a debt-to-equity ratio of 0.25, a current ratio of 10.43 and a quick ratio of 10.43. The company has a 50 day simple moving average of $20.08 and a two-hundred day simple moving average of $29.42.

uniQure (NASDAQ:QURE) last issued its quarterly earnings results on Monday, March 2nd. The biotechnology company reported ($0.56) EPS for the quarter, topping analysts’ consensus estimates of ($0.93) by $0.37. uniQure had a negative net margin of 1,236.00% and a negative return on equity of 174.03%. The firm had revenue of $5.57 million for the quarter, compared to analyst estimates of $4.84 million. Analysts expect that uniQure N.V. will post -3.75 earnings per share for the current fiscal year.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.